relied on the underlying cause of death stated on the death certificate but, because of the large body of literature suggesting inaccuracy in death certificates (Gittelsohn & Royston, 1982; Alderson & Meade, 1983; Cameron & McGoogan, 1981) a system for reassessing the cause of death was instituted. As the underlying cause of death is always somewhat conjectural, whereas the presence of breast cancer at death may be objectively demonstrated, the assessors were additionally asked to state whether breast cancer was present at death. This paper presents the findings of the assessors regarding the reliability of the death certificate and discusses the value of review.
Method of review
The TEDBC involves eight separate districts: Edinburgh and Guildford which provided screening, Huddersfield and Nottingham which provided education in breast self-examination (BSE) and four comparison districts, Oxford, Bristol, Southmead, Dundee and Stoke which offered no special intervention services. Details of method (UK Trial of Early Detection of Breast Cancer Group, 1981) and first results on mortality (UK Trial of Early Detection of Breast Cancer Group, 1988) are described elsewhere. The records of 99% of the women were successfully flagged at the NHS Central Registries and it is these women, aged 45 to 72, whose mortality has been analysed. For (Tabar et al., 1985; Tabar et al., 1989) (Table II) . If, however, in those cases where the assessors were uncertain because records were scanty, the certifying doctors were given the benefit of the doubt, the number of cases of disagreement between assessor and death certificate would have been reduced from 56 (6.0%), as shown in Table II , to 12 (1.3%). Table III Suspected false positive and false negative errors were almost equal in number and hence resulted in very little overall bias (i.e. less than 1%). If death with mention of breast cancer on the death certificate were to be used as end-point Table II shows that the number of errors would be slightly greater, 58 (6.3%), and there would be a slightly larger over-estimation bias, 2.7%, in comparison with the assessors' verdict of whether breast cancer was present or contributory.
Stage at diagnosis Table IV shows, as expected that the probability of death from breast cancer increased with advancing stage at diagnosis. The likelihood of finding false negative errors on the 
Discussion
The proportion of deaths with probable errors was 6% in this study whereas Brinkley et al. (1984) (OPCS, 1985) . As the rule was not adopted simultaneously in Scotland there is a slightly greater underestimation bias in Edinburgh than in the English centres.
The low rate of detectable error in reporting death from breast cancer in our study, confirms the findings of earlier studies (Bauer & Robbins, 1972; Cameron & McGoogan, 1981; Waaler & Grimstead, 1958) which showed that cancers are better recorded than other causes of death and that breast cancer is among the best recorded cancers. The error rate indicates that the certified cause of death provides an adequate end-point for evaluating breast screening programmes in the United Kingdom at least up to 8 years from entry. However the risk of errors may vary from place to place: in Utrecht a check on breast cancer deaths found that ten out of 56 were misclassified (Collette et al., 1984) due to illegible writing. It is also possible that the chance of overlooking breast cancer will increase in Britain as more women are treated by methods which leave less visible evidence. The visibility of the disease and of the scar left by treatment probably explain why the accuracy of death certificates in reporting breast cancer is so high (Engel et al., 1980) . Verification of the cause of death is now considered essen-tial for all subjects in trials of cancer treatments (Hayward et al., 1978) A major benefit of review mentioned by Hayward et al. (1978) , namely that knowledge that it will take place encourages better record keeping, was absent from this trial as it was impractical to keep all clinicians caring for breast cancer patients informed about the trial. Our study also may be criticised for not conducting 'blind' review but we consider that blinding would have added little to the reliability of our findings and might have hampered perusal of all relevant information. Bias due to inter-district variation in the thoroughness of investigation, exemplified by the variation in rates of histological confirmation and rates of autopsy shown in Table I , was of far greater concern. Increased autopsy would undoubtedly improve reliability though the error rate found in those actually autopsied exaggerates the inaccuracy of clinical diagnosis due to the selection of difficult cases for autopsy (Cameron & McGoogan, 1981) . Previous studies have commented on the greater inaccuracy of death certificates of patients who die at home (Jablon et al., 1966) , patients with a short hospital admission (Alderson & Meade, 1967) , and patients dying in non-teaching hospitals (Waldron & Vickerstaff, 1977) .
In the Swedish Two Counties trial and in New York, review was conducted by two or more independent assessors who were blinded to the source of the case. Blinding in these randomised trials was easier than in the UK trial because cases and controls were usually treated in the same institutions. However, even in the New York trial and the Two Counties trial the validity of reviewers conclusions are not immune from a bias which could favour screening. Both studies (Shapiro et al., 1988; Tabar et al., 1989) (Chamberlain, 1982) . The purpose of making populationbased mortality comparisons rather than case-fatality comparisons is the avoidance of lead time bias and length-biased sampling effects but, if stage is taken into consideration in judging between competing causes of death, review of the cause of death is unhelpful. Unfortunately there is no way to avoid this problem completely. Even with meticulous autopsy the origin of metastasis is judged on the basis of probability rather than on unique features of breast neoplasm. The number of cases with two cancers of different sites is, however, small (less than 6%, excluding skin cancers) in this study. We conclude that the certified underlying cause of death currently provides the most appropriate major end-point for evaluating screening programmes in England though possibly in Scotland death with mention of breast cancer is more appropriate. Assessment of the extent of bias by a method which avoids case-review will be discussed in a separate paper. Improvement in the monitoring and evaluation of screening in Britan will best be served by improving the cancer registration system in order to ascertain all new cases and their dates of diagnosis, rather than by organising independent review of case-notes of patients with breast cancer who die.
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